KNSA
USDKiniksa Pharmaceuticals International plc Class A Ordinary Shares
Real-time Price
Price Chart
Key Metrics
Market Metrics
Open
$39.080
High
$39.220
Low
$38.570
Volume
0.35M
Company Fundamentals
Market Cap
2.9B
Industry
Drug Manufacturers - Specialty & Generic
Country
United Kingdom
Trading Stats
Avg Volume
0.46M
Exchange
NMS
Currency
USD
52-Week Range
Related News
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $55
Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals with a Buy and raises the price target from $45 to $55.
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net product revenue raised to $670 - $675 million –– KPL-387 granted Orphan
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $44
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals with a Outperform and raises the price target from $38 to $44.
Related Stocks
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.